Detalhe da pesquisa
1.
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
N Engl J Med
; 386(6): 531-543, 2022 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34910859
2.
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine.
Clin Infect Dis
; 2024 Feb 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38372392
3.
COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials.
Clin Infect Dis
; 2024 Apr 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38598658
4.
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.
N Engl J Med
; 376(25): 2427-2436, 2017 06 22.
Artigo
Inglês
| MEDLINE | ID: mdl-28636855
5.
Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
J Infect Dis
; 216(10): 1219-1226, 2017 12 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28968871
6.
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines.
medRxiv
; 2024 Jan 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38293205
7.
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
JAMA Netw Open
; 7(5): e2412835, 2024 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38780941
8.
NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
Vaccine
; 41(22): 3461-3466, 2023 05 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37127523
9.
Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico.
medRxiv
; 2023 May 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37214968
10.
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
Vaccine
; 41(41): 5965-5973, 2023 09 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37652823
11.
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
JAMA Netw Open
; 6(4): e239135, 2023 04 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37099299
12.
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Expert Rev Vaccines
; 22(1): 501-517, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37246757
13.
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial.
Nat Commun
; 14(1): 331, 2023 01 19.
Artigo
Inglês
| MEDLINE | ID: mdl-36658109
14.
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
JAMA Netw Open
; 6(7): e2323349, 2023 Jul 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37440227
15.
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
Vaccine
; 41(33): 4899-4906, 2023 07 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37385888
16.
Risk of COVID-19 after natural infection or vaccination.
EBioMedicine
; 96: 104799, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37738833
17.
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial.
medRxiv
; 2022 Sep 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36172135
18.
Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.
J Infect Dis
; 201(4): 590-9, 2010 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-20064072
19.
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines.
J Infect
; 88(3): 106119, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38360356
20.
Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial.
Pediatrics
; 141(5)2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29610401